deucravacitinib,apremilast
bms,amgen
['psoriasis', 'deucrava', 'deucra', 'bristol']
bristol myers squibb announces new sotyktu (deucravacitinib) long-term data showing clinical efficacy maintained for up to two years with continuous treatment in moderate-to-severe plaque psoriasis 
Breaking news from Business Wire